Measles

Nature Reviews Disease Primers

Volumn 2, Issue , 2016, Pages

  Rota, Paul A ^a   Moss, William J ^b   Takeda, Makoto ^c   De Swart, Rik L ^d   Thompson, Kimberly M ^e,f   Goodson, James L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Kid Risk Inc   (United States)

^f UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; MEASLES VACCINE; VIRUS RNA;

AGE; ANTIGENIC VARIATION; ARTICLE; BLINDNESS; CASE FATALITY RATE; CHILDHOOD MORTALITY; COMMON COLD; CONJUNCTIVITIS; COUGHING; DEVELOPING COUNTRY; DISEASE SURVEILLANCE; ENCEPHALITIS; EPIDEMIC; GASTROENTERITIS; GENETIC VARIATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INDUSTRIALIZATION; INFECTION PREVENTION; INFECTION RISK; LABORATORY TEST; LIFE CYCLE; MACULOPAPULAR RASH; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; RNA VIRUS; SUBACUTE SCLEROSING PANENCEPHALITIS; VIRAL CLEARANCE; VIROLOGY; VIRUS IMMUNITY; VIRUS STRAIN; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; COMPLICATION; HISTORY; IMMUNOLOGY; INCIDENCE; NUTRITIONAL STATUS; PATHOGENICITY; PROCEDURES; RESPIRATORY TRACT INFECTION; TRANSMISSION; VACCINATION;

AGE FACTORS; EPIDEMICS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; MEASLES; MEASLES VIRUS; NUTRITIONAL STATUS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; VACCINATION;

EID: 85006207365     PISSN: None     EISSN: 2056676X     Source Type: Journal    
DOI: 10.1038/nrdp.2016.49     Document Type: Article

References (181)

1. Griffin, D. E. in Fields Virology (eds Fields, B. N., Howley, P. M., Cohen, J. I., Knipe, D. M.) 1042-1069 (Wolters Kluver/Lippincott Williams & Wilkins, 2013).
2. Chen, R. T., Goldbaum, G. M., Wassilak, S. G., Markowitz, L. E., Orenstein, W. A. An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease. Am. J. Epidemiol. 129, 173-182 (1989).
3. Bloch, A. B. et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 75, 676-683 (1985).
4. Wolfson, L. J. et al. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369, 191-200 (2007).
5. Mina, M. J., Metcalf, C. J., de Swart, R. L., Osterhaus, A. D., Grenfell, B. T. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 348, 694-699 (2015).
6. Imdad, A. et al. Impact of vitamin A supplementation on infant and childhood mortality. BMC Public Health 11 (Suppl. 3), S20 (2011).
7. Perry, R. et al. Progress toward regional measles elimination-worldwide, 2000-2014. MMWR Morb. Mortal. Wkly Rep. 64, 1246-1251 (2015).
8. World Health Organization. Progress towards regional measles elimination, worldwide, 2000-2014. Wkly Epidemiol. Rec. 90, 623-631 (2015).
9. [No authors listed.] Global vaccine action plan. Decade of vaccine collaboration. Vaccine 31 (Suppl. 2), B5-B31 (2013).
10. World Health Organization. Framework for verifying elimination of measles and rubella. Wkly Epidemiol. Rec. 88, 89-99 (2013).
11. Simons, E. et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 379, 2173-2178 (2012).
12. Perry, R. et al. Progress toward regional measles elimination-worldwide, 2000-2013. MMWR Morb. Mortal. Wkly Rep. 63, 1034-1038 (2014).
13. Mulders, M. et al. Global measles and rubella laboratory network support for elimination goals, 2010-2015. MMWR Morb. Mortal. Wkly Rep. 65, 438-442 (2016).
14. Fine, P. E., Clarkson, J. A. Measles in England and Wales-I: an analysis of factors underlying seasonal patterns. Int. J. Epidemiol. 11, 5-14 (1982).
15. Ferrari, M. J. et al. The dynamics of measles in sub-Saharan Africa. Nature 451, 679-684 (2008).
16. Bharti, N. et al. Explaining seasonal fluctuations of measles in Niger using nighttime lights imagery. Science 334, 1424-1427 (2011).
17. McLean, A. R., Anderson, R. M. Measles in developing countries. Part, I. Epidemiological parameters and patterns. Epidemiol. Infect. 100, 111-133 (1988).
18. McLean, A. R., Anderson, R. M. Measles in developing countries. Part, II. The predicted impact of mass vaccination. Epidemiol. Infect. 100, 419-442 (1988).
19. Smith, P. J., Marcuse, E. K., Seward, J. F., Zhao, Z., Orenstein, W. A. Children and adolescents unvaccinated against measles: geographic clustering, parents' beliefs, and missed opportunities. Public Health Rep. 130, 485-504 (2015).
20. Wallinga, J., Heijne, J. C., Kretzschmar, M. A measles epidemic threshold in a highly vaccinated population. PLoS Med. 2, e316 (2005).
21. Sutcliffe, P. A., Rea, E. Outbreak of measles in a highly vaccinated secondary school population. CMAJ 155, 1407-1413 (1996).
22. Thompson, K. M. Evolution and use of dynamic transmission models for measles and rubella risk and policy analysis. Risk Anal. http://dx.doi.org/10.1111/risa.12637 (2016).
23. Wolfson, L. J., Grais, R. F., Luquero, F. J., Birmingham, M. E., Strebel, P. M. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int. J. Epidemiol. 38, 192-205 (2009).
24. Salama, P. et al. Malnutrition, measles, mortality, and the humanitarian response during a famine in Ethiopia. JAMA 286, 563-571 (2001).
25. Caceres, V. M., Strebel, P. M., Sutter, R. W. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin. Infect. Dis. 31, 110-119 (2000).
26. Waaijenborg, S. et al. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J. Infect. Dis. 208, 10-16 (2013).
27. Leuridan, E., Van Damme, P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 25, 6296-6304 (2007).
28. Scott, S. et al. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin. Infect. Dis. 45, 1417-1424 (2007).
29. Moss, W. J. et al. Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin. Infect. Dis. 35, 189-196 (2002).
30. Permar, S. R. et al. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J. Infect. Dis. 183, 532-538 (2001).
31. Dossetor, J., Whittle, H. C., Greenwood, B. M. Persistent measles infection in malnourished children. Br. Med. J. 1, 1633-1635 (1977).
32. Garenne, M. Sex differences in measles mortality: a world review. Int. J. Epidemiol. 23, 632-642 (1994).
33. Haralambieva, I. H., Kennedy, R. B., Ovsyannikova, I. G., Whitaker, J. A., Poland, G. A. Variability in humoral immunity to measles vaccine: new developments. Trends Mol. Med. 21, 789-801 (2015).
34. Udem, S. A. Measles virus: conditions for the propagation and purification of infectious virus in high yield. J. Virol. Methods 8, 123-136 (1984).
35. Tatsuo, H., Ono, N., Tanaka, K., Yanagi, Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406, 893-897 (2000).
36. van der Vlist, M. et al. Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4+ T cells but are incapable of cross-presentation. Eur. J. Immunol. 41, 2619-2631 (2011).
37. Cannons, J. L., Tangye, S. G., Schwartzberg, P. L. SLAM family receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 29, 665-705 (2011).
38. Noyce, R. S. et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 7, e1002240 (2011).
39. Muhlebach, M. D. et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480, 530-533 (2011).
40. van der Vlist, M. et al. Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4+ T cells but are incapable of cross-presentation. Eur. J. Immunol. 41, 2619-2631 (2011).
41. de Witte, L., Abt, M., Schneider-Schaulies, S., van Kooyk, Y., Geijtenbeek, T. B. Measles virus targets DC-SIGN to enhance dendritic cell infection. J. Virol. 80, 3477-3486 (2006).
42. Dorig, R. E., Marcil, A., Chopra, A., Richardson, C. D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75, 295-305 (1993).
43. Yanagi, Y., Takeda, M., Ohno, S., Hashiguchi, T. Measles virus receptors. Curr. Top. Microbiol. Immunol. 329, 13-30 (2009).
44. de Swart, R. L. et al. Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of Macaques. PLoS Pathog. 3, e178 (2007).
45. de Vries, R. D., de Swart, R. L. Measles immune suppression: functional impairment or numbers game? PLoS Pathog. 10, e1004482 (2014).
46. de Vries, R. D. et al. In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J. Virol. 84, 4714-4724 (2010).
47. de Witte, L. et al. DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. PLoS Pathog. 4, e1000049 (2008).
48. Lemon, K. et al. Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog. 7, e1001263 (2011).
49. Leonard, V. H., Hodge, G., Reyes-Del Valle, J., McChesney, M. B., Cattaneo, R. Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J. Virol. 84, 3413-3420 (2010).
50. Leonard, V. H. et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J. Clin. Invest. 118, 2448-2458 (2008).
51. Ludlow, M. et al. Wild-type measles virus infection of primary epithelial cells occurs via the basolateral surface without syncytium formation or release of infectious virus. J. Gen. Virol. 91, 971-979 (2010).
52. Frenzke, M. et al. Nectin-4-dependent measles virus spread to the cynomolgus monkey tracheal epithelium: role of infected immune cells infiltrating the lamina propria. J. Virol. 87, 2526-2534 (2013).
53. Baxby, D. The diagnosis of the invasion of measles from a study of the exanthema as it appears on the buccal mucous membrane By Henry Koplik, M.D. Reproduced from Arch. Paed. 13, 918-922 (1886).
54. Rev. Med. Virol. 7, 71-74 (1997).
55. Singh, B. K. et al. The nectin-4/afadin protein complex and intercellular membrane pores contribute to rapid spread of measles virus in primary human airway epithelia. J. Virol. 89, 7089-7096 (2015).
56. Singh, B. K. et al. Cell-to-cell contact and nectin-4 govern spread of measles virus from primary human myeloid cells to primary human airway epithelial cells. J. Virol. 18 May 2016 [epub ahead of print].
57. De Vries, R. D., Mesman, A. W., Geijtenbeek, T. B., Duprex, W. P., de Swart, R. L. The pathogenesis of measles. Curr. Opin. Virol. 2, 248-255 (2012).
58. Ikegame, S. et al. Both RIG-I and MDA5 RNA helicases contribute to the induction of alpha/beta interferon in measles virus-infected human cells. J. Virol. 84, 372-379 (2010).
59. Plumet, S. et al. Cytosolic 5?-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. PLoS ONE 2, e279 (2007).
60. Yoneyama, M., Onomoto, K., Jogi, M., Akaboshi, T., Fujita, T. Viral RNA detection by RIG-I-like receptors. Curr. Opin. Immunol. 32, 48-53 (2015).
61. Parisien, J. P. et al. A shared interface mediates paramyxovirus interference with antiviral RNA helicases MDA5 and LGP2. J. Virol. 83, 7252-7260 (2009).
62. Sparrer, K. M., Pfaller, C. K., Conzelmann, K. K. Measles virus C protein interferes with beta interferon transcription in the nucleus. J. Virol. 86, 796-805 (2012).
63. Nakatsu, Y. et al. Measles virus circumvents the host interferon response by different actions of the C and V proteins. J. Virol. 82, 8296-8306 (2008).
64. Caignard, G. et al. Inhibition of IFN-α/b signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. Virology 383, 112-120 (2009).
65. Ohno, S., Ono, N., Takeda, M., Takeuchi, K., Yanagi, Y. Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. J. Gen. Virol. 85, 2991-2999 (2004).
66. Shaffer, J. A., Bellini, W. J., Rota, P. A. The C protein of measles virus inhibits the type I interferon response. Virology 315, 389-397 (2003).
67. Nakatsu, Y., Takeda, M., Ohno, S., Koga, R., Yanagi, Y. Translational inhibition and increased interferon induction in cells infected with C protein-deficient measles virus. J. Virol. 80, 11861-11867 (2006).
68. Takeuchi, K., Kadota, S. I., Takeda, M., Miyajima, N., Nagata, K. Measles virus V protein blocks interferon (IFN)-α/b but not IFN-? signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett. 545, 177-182 (2003).
69. Devaux, P., Hodge, G., McChesney, M. B., Cattaneo, R. Attenuation of V-or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J. Virol. 82, 5359-5367 (2008).
70. Ryon, J. J., Moss, W. J., Monze, M., Griffin, D. E. Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles. Clin. Diagn. Lab. Immunol. 9, 994-1003 (2002).
71. Vuorinen, T., Peri, P., Vainionpaa, R. Measles virus induces apoptosis in uninfected bystander T cells and leads to granzyme B and caspase activation in peripheral blood mononuclear cell cultures. Eur. J. Clin. Invest. 33, 434-442 (2003).
72. Fugier-Vivier, I. et al. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J. Exp. Med. 186, 813-823 (1997).
73. Manchester, M., Smith, K. A., Eto, D. S., Perkin, H. B., Torbett, B. E. Targeting and hematopoietic suppression of human CD34+ cells by measles virus. J. Virol. 76, 6636-6642 (2002).
74. Tamashiro, V. G., Perez, H. H., Griffin, D. E. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr. Infect. Dis. J. 6, 451-454 (1987).
75. Griffin, D. E., Ward, B. J. Differential CD4 T cell activation in measles. J. Infect. Dis. 168, 275-281 (1993).
76. Ferreira, C. S. et al. Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). J. Virol. 84, 3033-3042 (2010).
77. Coughlin, M. M., Bellini, W. J., Rota, P. A. Contribution of dendritic cells to measles virus induced immunosuppression. Rev. Med. Virol. 23, 126-138 (2013).
78. Hahm, B., Arbour, N., Oldstone, M. B. Measles virus interacts with human SLAM receptor on dendritic cells to cause immunosuppression. Virology 323, 292-302 (2004).
79. Servet-Delprat, C. et al. Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells. J. Immunol. 164, 1753-1760 (2000).
80. Hahm, B., Cho, J. H., Oldstone, M. B. Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. Virology 358, 251-257 (2007).
81. Hirsch, R. L. et al. Cellular immune responses during complicated and uncomplicated measles virus infections of man. Clin. Immunol. Immunopathol. 31, 1-12 (1984).
82. Erlenhoefer, C. et al. CD150 (SLAM) is a receptor for measles virus but is not involved in viral contact-mediated proliferation inhibition. J. Virol. 75, 4499-4505 (2001).
83. Griffin, D. E., Ward, B. J., Jauregui, E., Johnson, R. T., Vaisberg, A. Immune activation in measles. N. Engl. J. Med. 320, 1667-1672 (1989).
84. de Vries, R. D. et al. Measles immune suppression: lessons from the macaque model. PLoS Pathog. 8, e1002885 (2012).
85. Bankamp, B. et al. Wild-type measles viruses with non-standard genome lengths. PLoS ONE 9, e95470 (2014).
86. Rota, J. S. et al. Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. J. Infect. Dis. 173, 32-37 (1996).
87. Tamin, A. et al. Antigenic analysis of current wild type and vaccine strains of measles virus. J. Infect. Dis. 170, 795-801 (1994).
88. Shi, J. et al. Measles incidence rate and a phylogenetic study of contemporary genotype H1 measles strains in China: is an improved measles vaccine needed? Virus Genes 43, 319-326 (2011).
89. Santibanez, S. et al. Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? J. Gen. Virol. 86, 365-374 (2005).
90. Kuhne, M., Brown, D. W., Jin, L. Genetic variability of measles virus in acute and persistent infections. Infect. Genet. Evol. 6, 269-276 (2006).
91. Finsterbusch, T. et al. Measles viruses of genotype H1 evade recognition by vaccine-induced neutralizing antibodies targeting the linear haemagglutinin noose epitope. J. Gen. Virol. 90, 2739-2745 (2009).
92. Tahara, M. et al. The receptor-binding site of the measles virus hemagglutinin protein itself constitutes a conserved neutralizing epitope. J. Virol. 87, 3583-3586 (2013).
93. Tahara, M. et al. Functional and structural characterization of neutralizing epitopes of measles virus hemagglutinin protein. J. Virol. 87, 666-675 (2013).
94. Beaty, S. M., Lee, B. Constraints on the genetic and antigenic variability of measles virus. Viruses 8, 109 (2016).
95. Xu, S. et al. Evolutionary genetics of genotype H1 measles viruses in China from 1993 to 2012. J. Gen. Virol. 95, 1892-1899 (2014).
96. Zhang, Y. et al. Monitoring progress toward measles elimination by genetic diversity analysis of measles viruses in China 2009-2010. Clin. Microbiol. Infect. 20, O566-O577 (2014).
97. Bellini, W. J., Rota, P. A. Biological feasibility of measles eradication. Virus Res. 162, 72-79 (2011).
98. de Swart, R. L. et al. Measles in a Dutch hospital introduced by an immunocompromised infant from Indonesia infected with a new genotype virus. Lancet 355, 201-202 (2000).
99. Markowitz, L. E. et al. Fatal measles pneumonia without rash in a child with AIDS. J. Infect. Dis. 158, 480-483 (1988).
100. Featherstone, D., Brown, D., Sanders, R. Development of the Global Measles Laboratory Network. J. Infect. Dis. 187, S264-S269 (2003).
101. Griffin, D. E. Measles virus and the nervous system. Handb. Clin. Neurol. 123, 577-590 (2014).
102. Cutts, F. T., Henderson, R. H., Clements, C. J., Chen, R. T., Patriarca, P. A. Principles of measles control. Bull. World Health Organ. 69, 1-7 (1991).
103. van den Hof, S., Conyn-van Spaendonck, M. A., van Steenbergen, J. E. Measles epidemic in the Netherlands, 1999-2000. J. Infect. Dis. 186, 1483-1486 (2002).
104. Atmar, R. L., Englund, J. A., Hammill, H. Complications of measles during pregnancy. Clin. Infect. Dis. 14, 217-226 (1992).
105. Siegel, M., Fuerst, H. T. Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis. JAMA 197, 680-684 (1966).
106. Ogbuanu, I. U. et al. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009-2010. Clin. Infect. Dis. 58, 1086-1092 (2014).
107. Helfand, R. F. et al. Diagnosis of measles with an IgM capture EIA: the optimal timing of specimen collection after rash onset. J. Infect. Dis. 175, 195-199 (1997).
108. Rota, P. A. et al. Improving global virologic surveillance for measles and rubella. J. Infect. Dis. 204, S506-S513 (2011).
109. Van Binnendijk, R. S. et al. Evaluation of serological and virological tests in the diagnosis of clinical and subclinical measles virus infections during an outbreak of measles in the Netherlands. J. Infect. Dis. 188, 898-903 (2003).
110. Kobune, F., Sakata, H., Sugiura, A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J. Virol. 64, 700-705 (1990).
111. Ono, N. et al. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J. Virol. 75, 4399-4401 (2001).
112. Afzal, M. A. et al. Comparative evaluation of measles virus-specific RT-PCR methods through an international collaborative study. J. Med. Virol. 70, 171-176 (2003).
113. World Health Organization. Measles and rubella laboratory network: 2007 meeting on use of alternative sampling techniques for surveillance. Wkly Epidemiol. Rec. 83, 229-232 (2008).
114. De Swart, R. L. et al. Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnostic and epidemiological studies of measles. J. Clin. Microbiol. 39, 270-273 (2001).
115. Samuel, D. et al. Development of a measles specific IgM ELISA for use with serum and oral fluid samples using recombinant measles nucleoprotein produced in Saccharomyces cerevisiae. J. Clin. Virol. 28, 121-129 (2003).
116. Jin, L., Vyse, A., Brown, D. W. The role of RT-PCR assay of oral fluid for diagnosis and surveillance of measles, mumps and rubella. Bull. World Health Organ. 80, 76-77 (2002).
117. Ludlow, M. et al. Infection of lymphoid tissues in the macaque upper respiratory tract contributes to the emergence of transmissible measles virus. J. Gen. Virol. 94, 1933-1944 (2013).
118. Ludlow, M., McQuaid, S., Milner, D., de Swart, R. L., Duprex, W. P. Pathological consequences of systemic measles virus infection. J. Pathol. 235, 253-265 (2015).
119. Rota, P. A. et al. Global distribution of measles genotypes and measles molecular epidemiology. J. Infect. Dis. 204, S514-S523 (2011).
120. Greenwood, K. P., Hafiz, R., Ware, R. S., Lambert, S. B. A systematic review of human-to-human transmission of measles vaccine virus. Vaccine 34, 2531-2536 (2016).
121. Kutty, P. et al. VPD Surveillance Manual, 6th Edition Chapter 7: Measles. CDC https://stacks.cdc.gov/View/cdc/35640 (2013).
122. [No authors listed.] Genetic diversity of wild-type measles viruses and the global measles nucleotide surveillance database (MeaNS). Wkly Epidemiol. Rec. 90, 373-380 (2015).
123. Santibanez, S. et al. Long-term transmission of measles virus in Central and continental Western Europe. Virus Genes 50, 2-11 (2015).
124. Nic Lochlainn, L. et al. A unique measles B3 cluster in the United Kingdom and the Netherlands linked to air travel and transit at a large international airport, February to April 2014. Euro Surveill. 21, 30177 (2016).
125. Shulga, S. V. et al. Genetic variability of wild-type measles viruses, circulating in the Russian Federation during the implementation of the National Measles Elimination Program, 2003-2007. Clin. Microbiol. Infect. 15, 528-537 (2009).
126. Takashima, Y. et al. Progress toward measles elimination-Philippines, 1998-2014. MMWR Morb. Mortal. Wkly Rep. 64, 357-362 (2015).
127. Harvala, H. et al. Role of sequencing the measles virus hemagglutinin gene and hypervariable region in the measles outbreak investigations in Sweden during 2013-2014. J. Infect. Dis. 213, 592-599 (2016).
128. Penedos, A. R., Myers, R., Hadef, B., Aladin, F., Brown, K. E. Assessment of the utility of whole genome sequencing of measles virus in the characterisation of outbreaks. PLoS ONE 10, e0143081 (2015).
129. Gardy, J. L. et al. Whole-genome sequencing of measles virus genotypes H1 and D8 during outbreaks of infection following the 2010 Olympic winter games reveals viral transmission routes. J. Infect. Dis. 212, 1574-1578 (2015).
130. Strebel, P. M., Papania, M. J., Fiebelkorn, A. P., Halsey, N. A. in Vaccines: Expert Consult 6th edn (eds Plotkin, S. A., Orenstein, W. A., Offit, P. A.) 352-387 (Elsevier Saunders, 2012).
131. Forni, A., L., Schluger, N., W., Roberts, R. B. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin. Infect. Dis. 19, 454-462 (1994).
132. Krasinski, K., Borkowsky, W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 261, 2512-2516 (1989).
133. World Health Organization. Vitamin A Supplements: A Guide to Their Use in the Treatment and Prevention of Vitamin A Deficiency and Xerophthalmia 2nd edn (WHO Press, 1997).
134. Rumore, M. M. Vitamin A as an immunomodulating agent. Clin. Pharm. 12, 506-514 (1993).
135. Perry, R. T., Halsey, N. A. The clinical significance of measles: a review. J. Infect. Dis. 189, S4-S16 (2004).
136. Hussey, G. D., Clements, C. J. Clinical problems in measles case management. Ann. Trop. Paediatr. 16, 307-317 (1996).
137. Thompson, K. M., Odahowski, C. L. The costs and valuation of health impacts of measles and rubella risk management policies. Risk Anal. http://dx.doi. org/10.1111/risa.12459 (2015).
138. van den Ent, M. M., Brown, D. W., Hoekstra, E. J., Christie, A., Cochi, S. L. Measles mortality reduction contributes substantially to reduction of all cause mortality among children less than five years of age, 1990-2008. J. Infect. Dis. 204, S18-S23 (2011).
139. Keller-Stanislawski, B. et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine 32, 7057-7064 (2014).
140. Moss, W. J., Strebel, P. Biological feasibility of measles eradication. J. Infect. Dis. 204, S47-S53 (2011).
141. Okwo-Bele, J. M., Cherian, T. The expanded programme on immunization: a lasting legacy of smallpox eradication. Vaccine 29, D74-D79 (2011).
142. Robbins, F. C. Prospects for worldwide control of measles: discussion I. Clin. Infect. Dis. 5, 619-620 (1983).
143. Dowdle, W., Cochi, S. The principles and feasibility of disease eradication. Vaccine 29, D70-D73 (2011).
144. Strebel, P. M. et al. A world without measles. J. Infect. Dis. 204, S1-S3 (2011).
145. World Health Organization. Global measles and rubella strategic plan 2012-2020. WHO http://apps.who.int/iris/bitstream/10665/44855/1/9789241503396-eng.pdf (2012).
146. Choe, Y. J., Jee, Y., Oh, M.-d., Lee, J.-K. Measles elimination activities in the Western Pacific region: experience from the Republic of Korea. J. Korean Med. Sci. 30, S115-S121 (2015).
147. Goodson, J. L. et al. Research priorities for global measles and rubella control and eradication. Vaccine 30, 4709-4716 (2012).
148. Edens, C., Collins, M. L., Goodson, J. L., Rota, P. A., Prausnitz, M. R. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine 33, 4712-4718 (2015).
149. Larson, H. J., Jarrett, C., Eckersberger, E., Smith, D. M., Paterson, P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine 32, 2150-2159 (2014).
150. Smits, G. P., van Gageldonk, P. G., Schouls, L. M., van der Klis, F. R., Berbers, G. A. Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus. Clin. Vaccine Immunol. 19, 396-400 (2012).
151. Shonhai, A. et al. Investigation of a measles outbreak in Zimbabwe, 2010: potential of a point of care test to replace laboratory confirmation of suspected cases. Epidemiol. Infect. 143, 3442-3450 (2015).
152. Lam, E. et al. Development of a district-level programmatic assessment tool for risk of measles virus transmission. Risk Anal. http://dx.doi. org/10.1111/risa.12409 (2015).
153. Duintjer Tebbens, R. J. et al. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 33, 703-749 (2013).
154. Polack, F. P. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr. Res. 62, 111-115 (2007).
155. Stittelaar, K. J., De Swart, R. L., Osterhaus, A. D. M. E. Vaccination against measles: a neverending story. Expert Rev. Vaccines 1, 151-159 (2002).
156. Griffin, D. E., Pan, C. H. Measles: old vaccines, new vaccines. Curr. Top. Microbiol. Immunol. 330, 191-212 (2009).
157. Griffin, D. E. Current progress in pulmonary delivery of measles vaccine. Expert Rev. Vaccines 13, 751-759 (2014).
158. Lin, W. H. et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc. Natl Acad. Sci. USA 108, 2987-2992 (2011).
159. Low, N. et al. A randomized, controlled trial of an aerosolized vaccine against measles. N. Engl. J. Med. 372, 1519-1529 (2015).
160. Malczyk, A. H. et al. A highly immunogenic and protective middle east respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J. Virol. 89, 11654-11667 (2015).
161. Ramsauer, K. et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect. Dis. 15, 519-527 (2015).
162. Lorin, C. et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78, 146-157 (2004).
163. World Health Organization. Measles surveillance. WHO http://www.who.int/immunization/monitoring-surveillance/burden/vpd/surveillance-type/active/measles-standards/en/(2003).
164. Goodson, J. L., Seward, J. F. Measles 50 years after use of measles vaccine. Infect. Dis. Clin. North Am. 29, 725-743 (2015).
165. Hinman, A., Orenstein, W., Papania, M. Evolution of measles elimination strategies in the United States. J. Infect. Dis. 189, S17-S22 (2004).
166. Atkinson, W. L., Orenstein, W. A., Krugman, S. The resurgence of measles in the United States, 1989-1990. Annu. Rev. Med. 43, 451-463 (1992).
167. Papania, M. J. et al. Epidemiology of measles in the United States, 1997-2001. J. Infect. Dis. 189, S61-S68 (2004).
168. Papania, M. J. et al. Elimination of endemic measles, rubella, and congenital rubella syndrome from the western hemisphere: the US Experience. JAMA Pediatr. 168, 148-155 (2014).
169. Clemmons, N., Gastanaduy, P., Fiebelkorn, A., Redd, S., Wallace, G. Measles-United States, January 4-April 2, 2015. MMWR Morb. Mortal. Wkly Rep. 64, 373-376 (2015).
170. Smith, P. J. et al. Children and adolescents unvaccinated against measles: geographic clustering, parents' beliefs, and missed opportunities. Public Health Rep. 130, 485-504 (2015).
171. de Swart, R. L., Duprex, W. P., Osterhaus, A. D. Rinderpest eradication: lessons for measles eradication? Curr. Opin. Virol. 2, 330-334 (2012).
172. Barrett, T. Morbillivirus infections, with special emphasis on morbilliviruses of carnivores. Vet. Microbiol. 69, 3-13 (1999).
173. Weiss, R. A. The Leeuwenhoek Lecture 2001. Animal origins of human infectious disease. Phil. Trans. R. Soc. Lond. B Biol. Sci. 356, 957-977 (2001).
174. McNeill, W. H. Plagues and Peoples (Anchor, 1977).
175. Morens, D. M., Taubenberger, J. K. A forgotten epidemic that changed medicine: measles in the US Army, 1917-18. Lancet Infect. Dis. 15, 852-861 (2015).
176. World Health Organization. WHO/UNICEF estimates of national immunization coverage. WHO http://www. who.int/immunization/monitoring-surveillance/data/en (2016).
177. World Health Organization. The number of global measles cases reported to WHO. WHO http://apps. who.int/immunization-monitoring/globalsummary/timeseries/tsincidencemeasles.html (2016).
178. Hashiguchi, T. et al. Structure of the measles virus hemagglutinin bound to its cellular receptor SLAM. Nat. Struct. Mol. Biol. 18, 135-141 (2011).
179. Nakatsu, Y. et al. Intracellular transport of the measles virus ribonucleoprotein complex is mediated by Rab11A-positive recycling endosomes and drives virus release from the apical membrane of polarized epithelial cells. J. Virol. 87, 4683-4693 (2013).
180. Wakimoto, H. et al. F-actin modulates measles virus cell-cell fusion and assembly by altering the interaction between the matrix protein and the cytoplasmic tail of hemagglutinin. J. Virol. 87, 1974-1984 (2013).
181. Tahara, M., Takeda, M., Yanagi, Y. Altered interaction of the matrix protein with the cytoplasmic tail of hemagglutinin modulates measles virus growth by affecting virus assembly and cell-cell fusion. J. Virol. 81, 6827-6836 (2007).